MAP3K1 is altered in 3.56% of malignant solid tumor patients with MAP3K1 Loss present in 0.23% of all malignant solid tumor patients [4].

MAP3K1 Loss is an inclusion criterion in 16 clinical trials for malignant solid tumor, of which 13 are open and 3 are closed. Of the trials that contain MAP3K1 Loss and malignant solid tumor as inclusion criteria, 10 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (3 open) [5].

MAP3K1 is altered in 2.4% of non-small cell lung carcinoma patients with MAP3K1 Loss present in 0.07% of all non-small cell lung carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 6 are open and 2 are closed. Of the trials that contain MAP3K1 Loss and non-small cell lung carcinoma as inclusion criteria, 6 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

MAP3K1 is altered in 3.96% of melanoma patients [4].

MAP3K1 Loss is an inclusion criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain MAP3K1 Loss and melanoma as inclusion criteria, 3 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [5].

MAP3K1 is altered in 2.38% of ovarian carcinoma patients with MAP3K1 Loss present in 0.66% of all ovarian carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MAP3K1 Loss and ovarian carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 0.99% of non-hodgkin lymphoma patients [4].

MAP3K1 Loss is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MAP3K1 Loss and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [5].

MAP3K1 is altered in 8.12% of breast carcinoma patients with MAP3K1 Loss present in 0.23% of all breast carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MAP3K1 Loss and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 2.57% of low grade glioma patients with MAP3K1 Loss present in 0.15% of all low grade glioma patients [4].

MAP3K1 Loss is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP3K1 Loss and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 1.62% of thyroid gland carcinoma patients with MAP3K1 Loss present in 0.09% of all thyroid gland carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP3K1 Loss and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

MAP3K1 is altered in 2.52% of glioma patients with MAP3K1 Loss present in 0.08% of all glioma patients [4].

MAP3K1 Loss is an inclusion criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP3K1 Loss and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

MAP3K1 is altered in 0.97% of pancreatic carcinoma patients with MAP3K1 Loss present in 0.08% of all pancreatic carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MAP3K1 Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 3.86% of colorectal carcinoma patients with MAP3K1 Loss present in 0.07% of all colorectal carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MAP3K1 Loss and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 0.79% of histiocytic and dendritic cell neoplasm patients [4].

MAP3K1 Loss is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MAP3K1 Loss and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [5].

MAP3K1 is altered in 0.65% of poorly differentiated thyroid gland carcinoma patients with MAP3K1 Loss present in 0.69% of all poorly differentiated thyroid gland carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP3K1 is altered in 2.89% of bladder carcinoma patients with MAP3K1 Loss present in 0.2% of all bladder carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAP3K1 Loss and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MAP3K1 is altered in 8.15% of endometrial carcinoma patients with MAP3K1 Loss present in 0.19% of all endometrial carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 0.29% of myelodysplastic syndromes patients with MAP3K1 Loss present in 0.18% of all myelodysplastic syndromes patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP3K1 is altered in 2.65% of astrocytic tumor patients with MAP3K1 Loss present in 0.12% of all astrocytic tumor patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 2.33% of squamous cell lung carcinoma patients with MAP3K1 Loss present in 0.11% of all squamous cell lung carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 2.82% of diffuse glioma patients with MAP3K1 Loss present in 0.07% of all diffuse glioma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 2.93% of glioblastoma patients with MAP3K1 Loss present in 0.05% of all glioblastoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains MAP3K1 Loss and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MAP3K1 is altered in 0.6% of acute myeloid leukemia patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP3K1 is altered in 1.98% of anaplastic astrocytoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains MAP3K1 Loss and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP3K1 is altered in 4.06% of cutaneous melanoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 5.33% of embryonal rhabdomyosarcoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 1.15% of ganglioglioma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 1.69% of head and neck carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAP3K1 Loss and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MAP3K1 is altered in 1.09% of hepatocellular carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 0.91% of lymphoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MAP3K1 Loss and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 1.42% of multiple myeloma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP3K1 is altered in 0.54% of neuroblastoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP3K1 is altered in 1.81% of neuronal and mixed neuronal-glial tumors patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 2.45% of pilocytic astrocytoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 1.23% of renal cell carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 1.39% of sarcoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MAP3K1 Loss and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 1.25% of soft tissue sarcoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP3K1 is altered in 1.72% of thyroid gland undifferentiated (anaplastic) carcinoma patients [4].

MAP3K1 Loss is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 Loss and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].